Health Condition 1: L910- Hypertrophic scar
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient with single keloid or multiple (upper limit 5) of more than 6-month duration. Every keloid selected for study is considered a different entity. 2. Keloids of size 3. The patient who can give valid consent.
Exclusion criteria
Exclusion criteria: 1. Patient with any previous interventional treatment for the same keloid in the 6 months preceding enrollment 2. Pregnant or lactating females or women who are planning a pregnancy 3. Keloids on the face 4. Immunosuppressed patients 5. Patient with chronic inflammatory diseases; patients with a history of renal or liver failure 6.Patients with a history of hypersensitivity to any of the study drugs 7. Patients with a history of non-responsiveness to any of the treatment modalities 8. The patient who is not willing to provide consent for the study. 9. Patient with active inflammation, infection, or ulcer in and around the keloid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patient achieving 50% reduction in scar score by measuring the difference in Vancouver scar scale in the group receiving intralesional injection vitamin D3 versus the injection triamcinolone group.Timepoint: At the end of 4,8,12,16,24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events during the treatmentTimepoint: At the end of 4,8,12,16,24 weeks;Mean difference in quality of life of patients before and after treatmentTimepoint: At the end of 4,8,12,16,24 weeks;To determine differences in VDR expression in keloid pathology by comparing tissue VDR expression pre and post-treatmentTimepoint: At the end of 4,8,12,16,24 weeks | — |
Countries
India
Contacts
PGIMER CHANDIGARH